Evotec (EVO)
(Delayed Data from NSDQ)
$3.71 USD
0.00 (0.00%)
Updated Aug 30, 2024 11:51 AM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Evotec AG (EVO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$8.14 | $15.00 | $3.00 | 119.41% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Evotec AG comes to $8.14. The forecasts range from a low of $3.00 to a high of $15.00. The average price target represents an increase of 119.41% from the last closing price of $3.71.
Analyst Price Targets (5 )
Broker Rating
Evotec AG currently has an average brokerage recommendation (ABR) of 2.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 2.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 12.5% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 12.5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/EVO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 5 | 5 |
Buy | 1 | 1 | 1 | 2 | 2 |
Hold | 1 | 1 | 2 | 0 | 0 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 0 | 0 | 0 |
ABR | 2.25 | 2.25 | 2.00 | 1.56 | 1.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/15/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
5/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/17/2024 | Not Identified | Not Identified | Hold | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.25 |
ABR (Last week) | 2.25 |
# of Recs in ABR | 8 |
Average Target Price | $8.14 |
LT Growth Rate | 49.70% |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -0.08 |